Atlas Arteria

As of December 31, 2025, Atlas Arteria carries a market capitalization of 3.85B, placing it among publicly traded companies globally. Its enterprise value stands at 6.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Atlas Arteria's next confirmed earnings release is scheduled for February 24, 2027.

As of December 31, 2025, Atlas Arteria has 1.45B shares outstanding.

As of December 31, 2025, Atlas Arteria trades at a trailing price-to-earnings ratio of 26.09. The price-to-sales ratio is 42.60, and the price-to-book ratio stands at 2.18.

As of December 31, 2025, Atlas Arteria trades at an EV/EBITDA multiple of 225.37 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 68.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.21B versus a market cap of 3.85B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Atlas Arteria maintains a current ratio of 2.17, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.96, indicating elevated leverage, while an interest coverage ratio of 0.50 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Atlas Arteria posted a return on equity (ROE) of 8.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.29, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 3.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.49, useful for judging operating efficiency across full business cycles.

Over the twelve months ended December 31, 2025, Atlas Arteria recorded 4.54M in income tax expense. That works out to an effective tax rate of 4.21, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 107.83M, leaving 147.43M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 22, 2026, Atlas Arteria's stock has declined approximately 7.14% over the past 52 weeks. The 50-day moving average sits at 2.79, while the 200-day moving average is 2.74.

Over the twelve months ended December 31, 2025, Atlas Arteria generated 90.27M in revenue and converted that into 147.43M in net income, yielding earnings per share of 0.07. EBITDA reached 27.55M, while operating income came in at -13.29M.

As of December 31, 2025, Atlas Arteria holds 155.89M in cash and equivalents against 987.62M in total debt, resulting in a net debt position of 816.33M. Total book value stands at 1.76B, with working capital of 88.46M providing operational flexibility.

These figures cover the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Atlas Arteria posted a gross margin of 86.03, reflecting its pricing power and cost economics. The operating margin of -14.73 and net profit margin of 163.31 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, Atlas Arteria paid dividends of 0.23 per share. The dividend payout ratio of 557.54 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 10.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Atlas Arteria shareholders.

Atlas Arteria's most recent stock split took place on September 16, 2022.

As of December 31, 2025, Atlas Arteria has an Altman Z-Score of 1.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.